Table 2.

Effectiveness of disease-modifying therapies on EDSS disability progression, relapses, new lesions, and brain volume loss.

Therapy Family	Relative Risk of Disability Progression c	Rate Ratio for Relapse Rate c	Rate Ratio for New Lesions d	aPBVC e
low efficacy a	0.52–1.23	0.55–0.94	0.32–0.89	−0.51% ± 0.27%
high efficacy b	0.25–0.90	0.22–0.63	0.06–0.42	−0.27% ± 0.15%

^a Beta interferon, glatiramer acetate, teriflunomide are included. ^b Alemtuzumab, natalizumab, ocrelizumab are included. ^c Values are pooled from [17], taking the minimum and maximum bounds from the intervals given for different DMTs in the 2 considered DMT families. See also Appendix A Table A4. ^d Values are estimated based on the relationship between the relative treatment effect on MRI lesions and the relative treatment effect on relapses, log (relapse_effect) = 0.53 log (lesions_effect) [31]; in other words, the values in columns 3 and 4 are linked through this equation. ^e Mean ± standard deviation of Gaussian distributions are taken from [22].